Exco InTouch Formally Receives US - European Union/Swiss Safe Harbor Certification for Data Protection - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
Exco InTouch Formally Receives US - European Union/Swiss Safe Harbor Certification for Data Protection

Source: Company News Release

Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has now formally received U.S.- EU Safe Harbor Framework and U.S.- Swiss Safe Harbor Framework Self Certification status by the U.S. Department of Commerce’s International Trade Administration (ITA). The designation certifies that Exco InTouch’s practices meet or exceed the data privacy and security standards outlined by The European Commission’s Directive on data protection.

The U.S. Department of Commerce, in consultation with the European Commission, developed the Safe Harbor framework in order to bridge the gap between EU/Switzerland and U.S. approaches to privacy protection and provide a streamlined means for U.S. organisations to comply with the Commission’s Directive. In order to be recognised for the certification, Exco InTouch has demonstrated that its customer privacy procedures comply with the seven ‘Safe Harbor Privacy Principles’ which cover notice, choice, transfers to third parties, access, security, data integrity and enforcement. As a result, Exco InTouch’s customers, for whom the company provides mobile and digital patient engagement solutions, can be reassured that their programs comply with these stringent privacy and security safeguards.

“Protecting the privacy and confidentiality of personal information has always been, and will remain, the highest priority for Exco InTouch,” says Mike Hansen, COO and Co-Founder of Exco InTouch. “The U.S. – EU and US – Swiss Safe Harbor Certification will not only help to streamline our data transfer processes between the EU/Switzerland and U.S, but will also provide our customers with further reassurance that we are fully compliant with the highest standards of data protection.”

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here